The overall reduction in the expression of ARS was found to be related to prostate cancer aggressiveness, due to the association between ARSB and the epidermal growth factor receptor (EGFR), commonly overexpressed when ARSB is reduced [58,59]. Here, EGFR is linked to prostate cancer.